When starting prostaglandin E1 (PGE1) and during treatment with this drug, the clinical team should monitor vital signs such as blood pressure, heart rate, temperature, respiration, signs of penile pain, fibrosis, and infection. They should also evaluate the effectiveness following dosing and the duration of an achieved erection.

For IV injection to address PDA, the infant's respiratory status requires monitoring.